Lenti-Trh4 TCR (LnB5)-VP (VP-TCR-C038)

The ready-to-use lentiviral particles of Lenti-Trh4 TCR (LnB5)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Mouse TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


  • Type of Therapeutics
  • T cell receptor
  • Target
  • Trh4
  • Clone
  • LnB5
  • Promotor
  • CMV
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Cancer


  • Introduction
  • CerS5 robustly synthesizes C16-ceramide, which is often considered to be an important pro-apoptotic ceramide. De novo ceramide synthesis is an essential trigger for Bax activation in hypoxia/reoxygenation. Following hypoxia/reoxygenation, CerS5 expression is elevated. Upon knocking down acid sphingomyelinase and CerS5 in NTERA-2cells, Bax localization to mitochondria was reduced, indicating the importance of CerS5 activity in the apoptosis pathway.
  • Alternative Names
  • Trh4; Cers5; ceramide synthase 5

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.